के संबंध में कोई अंतिम निर्णय, बी.आई.एफ.आर., जो एक न्यायिक कल्प प्राधिकरण है, के समक्ष लम्बित कार्यवाहियों के निष्कर्ष पर निर्भर है।

HAL'S inability to manufacture adequate penicilin

2287. SHRI CHIMANBHAI MEHTA:
SHRIMATI RENUKA CHOWDHURY:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state;

(a) whether it is a fact that Hindustan antibiotics Ltd. has not been able to manufacture Penicillin to the fullest extent possible;

(b) if so, the reasons therefor;

(c) whether the reasons for low output include high contamination rate, low yield per unit of time, low recovery in post-fermentation process and high specific energy consumption;

(d) whether the HAL is negotiating modernisation with MAX-GB;

(e) whether it is a fact that MAX-GB proposed to offer a lease rent for Penicillin in a joint ventures at Rs. 7 crores;

(f) whether it is a fact that experts Committee appointed by Government to evaluate MAX GB's offer estimated the fair rent to be Rs. 32 crores a year (Net of taxes) and yet MOU is proposed by HAL to be signed with Max GB at Rs. 13 crores a year;

(g) whether it is a fact that Max GB had assessed value of HAL's assets initially at Rs. 27 crores and subsequently, to outbid other competitors, had reassessed HAL's assets value at Rs. 170 crores; and

(h) whether it is also a fact that SPIC and BPGL have requested HAL management to allow them to inspect the HAL's plant for assessing which was rejected while Max GB was permitted?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (h) The utilisation of rated capacity of penicillin-G of Hindustan Antibiotics Limited (HAL) in recent years has been over 80 per cent.

A Memorandum of Understanding (MOU) has been entered into between Hindustan Antibiotics Limited and MAX-GB for technology upgradation in the existing plant of HAL through a Joint Venture Collaboration. This is subject to approval of the Government which has not yet been given. The matter relating to the proposed Joint Venture between HAL and MAX-GB is before the Hon'ble High Court of Delhi through writ Petitions No. C.W. 3160/94, 3161/94 and 3181/94. The Union of India is the first Respondent in all the three Petitions. The Notices of the Court in respect of these writ Petitions have been received by the Government on the 5th August, 1994.

Anti Tuberculosis Drug Rifampicin

2288. SHRI S. S. AHLUWALIA: Will the Minister for CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that the vital anti tuberculosis drug, Rifampicin, is manufactured by using 'Rifa-S' as its key intermediate raw-material, which is imported solely and in accordance with the import policy of Government;

(b) whether it is also a fact that though on expiry of the earlier import policy relating to 'Rifa-S' new import regime should have come into effect from the 1st April, 1994, the same has not been materialised so far;

(c) if so, the reasons attributable thereto;

(d) whether it is also a fact that India, having the largest incidence of